Supernus Pharmaceuticals(US:SUPN) Globenewswireยท2025-07-22 20:30Company Overview - Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases [4] - The company's diverse neuroscience portfolio includes approved treatments for ADHD, dyskinesia in Parkinson's disease, hypomobility in Parkinson's disease, epilepsy, migraine, cervical dystonia, and chronic sialorrhea [5] Upcoming Financial Results - The company expects to report financial and business results for the second quarter of 2025 after the market closes on August 5, 2025 [1] - A conference call will be hosted by the President and CEO, Jack Khattar, and Senior Vice President and CFO, Tim Dec, on August 5, 2025, at 4:30 p.m. ET to present these results [2] Investor Relations - A live webcast of the conference call will be accessible on the company's Investor Relations website [2] - Participants can pre-register for the call and will receive a dial-in number with a personalized conference code [3]